Business
Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer
Firm to target small to medium-sized biotech and pharma companies Drew Reina, CRO at Velocity Clinical Research Drew Reina, CRO at Velocity Clinical Research DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world’s leading contract research organizations (CROs), where
About this update from Fortrea Holdings Inc.
[{"type":"text","content":"Firm to target small to medium-sized biotech and pharma companies","length":65,"tagName":"p"},{"type":"text","content":"Drew Reina, CRO at Velocity Clinical Research","length":45,"tagName":"p"},{"type":"image","alt":"Drew Reina, CRO at Velocity Clinical Research","displaySize":"","headline":null,"caption":"Drew Reina, CRO at Velocity Clinical Research","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1080,"height":1080,"url":"https://media.zenfs.com/en/globenewswire.com/08f90feb7f7e06016c08be9e60463bc8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3IjcDbDoHfI40rVbTYc9sA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/08f90feb7f7e06016c08be9e60463bc8","width":960,"height":960},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lLPe6kLuaHJsDu.TAOFuAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxNjA7aD0yMTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/08f90feb7f7e06016c08be9e60463bc8","width":1080,"height":1080}}},{"type":"text","content":"DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world’s leading contract research organizations (CROs), where he held senior leadership roles driving growth strategies and global business development.","length":433,"tagName":"p"},{"type":"text","content":"This appointment represents a pivotal milestone in Velocity’s evolution. The organization aims to set the standard for strategic relationships between multisite clinical research corporations (MCRCs), Sponsors, and CRO partners. Andrew will lead the revenue and partnership strategy, aligning patient recruitment expectations with strategic delivery for biotech and leading pharma companies, as well as small to medium-sized Sponsors and CROs.","length":443,"tagName":"p"},{"type":"text","content":"Paul Evans, PhD, President & CEO of Velocity, commented: “This has been a challenging year for clinical research in many ways. Andrew’s experience at Fortrea brings deep CRO-centric leadership to our senior team, and his appointment is a key step in positioning Velocity not just as an exceptional site network, but as ...